Live Attenuated Vaccines
The global Live Attenuated Vaccines market was valued at 2565.66 Million USD in 2021 and will grow with a CAGR of 6.11% from 2021 to 2027, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact wwhich will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable (or "live"). Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the virus (inactivated vaccine).Examples of live attenuated) vaccines includeViralmeasles vaccine, mumps vaccine, rubella vaccine and live attenuated influenza vaccine (the seasonal flu nasal spray and the 2009 H1N1 flu nasal spray), etc; BacterialBCG vaccine, oral typhoid vaccine and epidemic typhus vaccine.
By Market Verdors
GlaxoSmithKline
Merck
Pfizer
Astellas Pharma
Johnson & Johnson
CSL
Sanofi
Serum Institute Of India
By Types
Bacterial
Viral
By Applications
Hospitals
Clinics
Research Institutes
Key Indicators Analysed
Market Players & Competitor AnalysisThe report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market AnalysisThe report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market TrendsMarket key trends which include Increased Competition and Continuous Innovations.
Opportunities and DriversIdentifying the Growing Demands and New Technology
Porters Five Force AnalysisThe report provides with the state of competition in industry depending on five basic forcesthreat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements
Table of Content
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Live Attenuated Vaccines Revenue
1.4 Market Analysis by Type
1.4.1 Global Live Attenuated Vaccines Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Bacterial
1.4.3 Viral
1.5 Market by Application
1.5.1 Global Live Attenuated Vaccines Market Share by Application: 2022-2027
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Research Institutes
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Live Attenuated Vaccines Market
1.8.1 Global Live Attenuated Vaccines Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Live Attenuated Vaccines Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Live Attenuated Vaccines Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Live Attenuated Vaccines Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Live Attenuated Vaccines Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Live Attenuated Vaccines Sales Volume Market Share by Region (2016-2021)
3.2 Global Live Attenuated Vaccines Sales Revenue Market Share by Region (2016-2021)
3.3 North America Live Attenuated Vaccines Sales Volume
3.3.1 North America Live Attenuated Vaccines Sales Volume Growth Rate (2016-2021)
3.3.2 North America Live Attenuated Vaccines Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Live Attenuated Vaccines Sales Volume
3.4.1 East Asia Live Attenuated Vaccines Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Live Attenuated Vaccines Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Live Attenuated Vaccines Sales Volume (2016-2021)
3.5.1 Europe Live Attenuated Vaccines Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Live Attenuated Vaccines Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Live Attenuated Vaccines Sales Volume (2016-2021)
3.6.1 South Asia Live Attenuated Vaccines Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Live Attenuated Vaccines Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Live Attenuated Vaccines Sales Volume (2016-2021)
3.7.1 Southeast Asia Live Attenuated Vaccines Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Live Attenuated Vaccines Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Live Attenuated Vaccines Sales Volume (2016-2021)
3.8.1 Middle East Live Attenuated Vaccines Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Live Attenuated Vaccines Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Live Attenuated Vaccines Sales Volume (2016-2021)
3.9.1 Africa Live Attenuated Vaccines Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Live Attenuated Vaccines Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Live Attenuated Vaccines Sales Volume (2016-2021)
3.10.1 Oceania Live Attenuated Vaccines Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Live Attenuated Vaccines Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Live Attenuated Vaccines Sales Volume (2016-2021)
3.11.1 South America Live Attenuated Vaccines Sales Volume Growth Rate (2016-2021)
3.11.2 South America Live Attenuated Vaccines Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Live Attenuated Vaccines Sales Volume (2016-2021)
3.12.1 Rest of the World Live Attenuated Vaccines Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Live Attenuated Vaccines Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Live Attenuated Vaccines Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Live Attenuated Vaccines Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Live Attenuated Vaccines Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Live Attenuated Vaccines Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Live Attenuated Vaccines Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Live Attenuated Vaccines Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Live Attenuated Vaccines Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Live Attenuated Vaccines Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Live Attenuated Vaccines Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Live Attenuated Vaccines Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Live Attenuated Vaccines Sales Volume Market Share by Type (2016-2021)
14.2 Global Live Attenuated Vaccines Sales Revenue Market Share by Type (2016-2021)
14.3 Global Live Attenuated Vaccines Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Live Attenuated Vaccines Consumption Volume by Application (2016-2021)
15.2 Global Live Attenuated Vaccines Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Live Attenuated Vaccines Business
16.1 GlaxoSmithKline
16.1.1 GlaxoSmithKline Company Profile
16.1.2 GlaxoSmithKline Live Attenuated Vaccines Product Specification
16.1.3 GlaxoSmithKline Live Attenuated Vaccines Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Merck
16.2.1 Merck Company Profile
16.2.2 Merck Live Attenuated Vaccines Product Specification
16.2.3 Merck Live Attenuated Vaccines Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Pfizer
16.3.1 Pfizer Company Profile
16.3.2 Pfizer Live Attenuated Vaccines Product Specification
16.3.3 Pfizer Live Attenuated Vaccines Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Astellas Pharma
16.4.1 Astellas Pharma Company Profile
16.4.2 Astellas Pharma Live Attenuated Vaccines Product Specification
16.4.3 Astellas Pharma Live Attenuated Vaccines Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Johnson & Johnson
16.5.1 Johnson & Johnson Company Profile
16.5.2 Johnson & Johnson Live Attenuated Vaccines Product Specification
16.5.3 Johnson & Johnson Live Attenuated Vaccines Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 CSL
16.6.1 CSL Company Profile
16.6.2 CSL Live Attenuated Vaccines Product Specification
16.6.3 CSL Live Attenuated Vaccines Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Sanofi
16.7.1 Sanofi Company Profile
16.7.2 Sanofi Live Attenuated Vaccines Product Specification
16.7.3 Sanofi Live Attenuated Vaccines Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Serum Institute Of India
16.8.1 Serum Institute Of India Company Profile
16.8.2 Serum Institute Of India Live Attenuated Vaccines Product Specification
16.8.3 Serum Institute Of India Live Attenuated Vaccines Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Live Attenuated Vaccines Manufacturing Cost Analysis
17.1 Live Attenuated Vaccines Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Live Attenuated Vaccines
17.4 Live Attenuated Vaccines Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Live Attenuated Vaccines Distributors List
18.3 Live Attenuated Vaccines Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Live Attenuated Vaccines (2022-2027)
20.2 Global Forecasted Revenue of Live Attenuated Vaccines (2022-2027)
20.3 Global Forecasted Price of Live Attenuated Vaccines (2016-2027)
20.4 Global Forecasted Production of Live Attenuated Vaccines by Region (2022-2027)
20.4.1 North America Live Attenuated Vaccines Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Live Attenuated Vaccines Production, Revenue Forecast (2022-2027)
20.4.3 Europe Live Attenuated Vaccines Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Live Attenuated Vaccines Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Live Attenuated Vaccines Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Live Attenuated Vaccines Production, Revenue Forecast (2022-2027)
20.4.7 Africa Live Attenuated Vaccines Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Live Attenuated Vaccines Production, Revenue Forecast (2022-2027)
20.4.9 South America Live Attenuated Vaccines Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Live Attenuated Vaccines Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Live Attenuated Vaccines by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Live Attenuated Vaccines by Country
21.2 East Asia Market Forecasted Consumption of Live Attenuated Vaccines by Country
21.3 Europe Market Forecasted Consumption of Live Attenuated Vaccines by Countriy
21.4 South Asia Forecasted Consumption of Live Attenuated Vaccines by Country
21.5 Southeast Asia Forecasted Consumption of Live Attenuated Vaccines by Country
21.6 Middle East Forecasted Consumption of Live Attenuated Vaccines by Country
21.7 Africa Forecasted Consumption of Live Attenuated Vaccines by Country
21.8 Oceania Forecasted Consumption of Live Attenuated Vaccines by Country
21.9 South America Forecasted Consumption of Live Attenuated Vaccines by Country
21.10 Rest of the world Forecasted Consumption of Live Attenuated Vaccines by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices